Brief: Decibel Therapeutics Submits IND Application For Lead Gene Therapy Candidate
20/09/2022 12:24
Sept 20 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS ANNOUNCES SUBMISSION OF
INVESTIGATIONAL NEW
DRUG (IND) APPLICATION FOR LEAD GENE THERAPY CANDIDATE DB-OTO
Source text for Eikon: ID:nGNX517dng
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary